Stage IV endometrial carcinoma: A 10 year review of patients

British Journal of Radiology

Volumn 72, Issue MAY, 1999, Pages 485-488

  Cook, A M ^a   Lodge, N ^a   Blake, P ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; GESTAGEN;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; ENDOMETRIUM CANCER; FEMALE; HUMAN; LUNG METASTASIS; POSTOPERATIVE CARE; PROGNOSIS;

EID: 0032972945     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr.72.857.10505014     Document Type: Article

References (17)

1. Thomas R, Blake P. Endometrial carcinoma: adjuvant locoregional therapy. Clin Oncol 1996;8:140-5.
2. Goff BA, Goodman A, Muntz HG, Fuller AF, Nikrui N, Rice LW. Surgical stage IV endometrial carcinoma: a study of 47 cases. Gynecol Oncol 1994;52:237-40.
3. Rose PG. Endometrial carcinoma. NEJM 1996; 335(9):640-9.
4. McCabe JB, Sagerman RH. Treatment of endometrial cancer in a regional radiation therapy center. Cancer 1979;43:1052-7.
5. Vardi JR, Tadros GH, Anselmo MT, Rafla SD. The value of exploratory laparotomy in patients with endometrial cancer according to the new International Federation of Gynecology and Obstetrics Staging. Obstet Gynecol 1992;80:204-8.
6. Connelly PJ, Alberhasky RC, Christopherson WM. Carcinoma of the endometrium III. Analysis of 865 cases of adenocarcinoma and adenoacanthoma. Obstet Gynecol 1982;59:569-75.
7. Pliskow S, Penalver M, Averette HE. Stage III and IV endometrial carcinoma: a review of 41 cases. Gynecol Oncol 1990;38:210-15.
8. Truskett ID, Constable WC. Management of carcinoma of the corpus uterus. Am J Obstet Gynecol 1968;101:689-94.
9. Aalders JG, Abeler V, Kolstad P. Stage IV endometrial carcinoma: a clinical and histopathological study of 83 patients. Gynecol Oncol 1984; 17:75-84.
10. Malkasian GD, McDonald TW, Pratt JH. Carcinoma of the endometrium Mayo Clinic Experience. Mayo Clin Proc 1977;52:175-80.
11. International Federation of Gynecology and Obstetrics. Annual report on the treatment of gynecologic cancer 1989;28:189-90.
12. Duk JM, Aalders JG, Fleuren GJ, de Bruijn HWA. CA125: a useful marker in endometrial carcinoma. Am J Obstet Gynecol 1986;1097-1102.
13. Thigpen JT, Buchsbaum HJ, Managan C, Blessing JA. Phase II trial of Adriamycin in the treatment of advanced or recurrent endometrial carcinoma. A GOG study. Cancer Treat Rep 1979;63:21.
14. Seski JC, Edwards CL, Herson J, Rutledge FN. Cisplatin chemotherapy for disseminated endometrial carcinoma. Obstet Gynecol 1982;59:225.
15. Edmunson JH, Krook JE, Hilton JF, Malkasian GD, Eveson LK, Jeffries JA, et al. Randomized phase II studies of cisplatin and a combination of cyclophosphamide-doxorubicin-cisplatin (CAP) in patients with progestin-refractory advanced endometrial carcinoma. Gynecol Oncol 1987;28:20-4.
16. Green JB, Green S, Alberts DS, O'Toole R, Surwit EA, Noltimier JW. Carboplatin therapy in advanced endometrial cancer. Obstet Gynecol 1990;75:696-700.
17. Burke TW, Munkarah A, Kavanagh JJ, Morris M, Levenback C, Tornos C, et al. Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin. Gynecol Oncol 1993;51:397-400.